26 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 BIOTECH STARTUPS Biotech startups have always embraced cutting edge innovation as a way to push beyond current thinking, advance science and propel technology to greater heights. But not even the greatest minds could’ve predicted the technological era these companies are stepping into – one that is defined by artificial intelligence (AI), precision medicine, and a complete rethink as to how therapies are developed and delivered. As industry’s finest gather at DCAT Week, the spotlight falls on a number of early-stage companies eager to push these boundaries, fuelled on by the potential breakthroughs and the opportunity to redefine the way medicine works. Innovations and trends redefining the industry AI, machine learning, and personalised medicine are at the core of biotech’s transformation into a datadriven, precision-focused industry that redefine the boundaries of cell and gene therapy. As a senior executive at a leading German pharmaceutical company recently stated: “We are full of expectations for personalised medicine. With advances in genomics and biomarkers, we can provide patients with more precise treatment options. This not only improves efficacy but also significantly reduces side-effects, allowing patients to have a better treatment experience.” If economists are to be believed, gloomy economic forecasts coupled with the impact of trade policies and tariffs suggest investment in biotech will suffer a marked slowdown by influencing capital availability, regulatory landscapes, and market sentiment. However, so far in 2025, this doesn’t appear to be the case. Venture capital investment in biotech remains strong with research conducted by HSBC Innovation Banking indicating that venture capital (VC) investment in biotech remains robust in 2025. In 2024, U.S. and European biotech venture funding climbed to $28.1 billion from $21.2 billion the prior year. Current sentiment appears favourable towards the actions taken by regulatory bodies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which are streamlining approval processes through adaptive trial designs,
RkJQdWJsaXNoZXIy MjY2OTA4MA==